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Case Report
Clinical Microbiology
The First Korean Case of Candidemia due to Candida 
dubliniensis
Nae Yu, M.D., Hye Ryoun Kim, M.D., and Mi-Kyung Lee, M.D.
Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Korea
Candidemia due to uncommon Candida spp. appears to be increasing in incidence. C. 
dubliniensis has been increasingly recovered from individuals not infected with HIV. Iden-
tification of C. dubliniensis can be problematic in routine clinical practice due to its phe-
notypic resemblance to C. albicans. We report the first case of C. dubliniensis candidemia 
in Korea, which occurred in a 64-yr-old woman who presented with partial seizure, drowsi-
ness, and recurrent fever. Germ-tube positive yeast that was isolated from blood and cen-
tral venous catheter tip cultures formed smooth, white colonies on sheep blood agar and 
Sabouraud agar plates, indicative of Candida spp. C. dubliniensis was identified using the 
Vitek 2 system (bioMerieux, USA), latex agglutination, chromogenic agar, and multiplex 
PCR. The blood isolate was susceptible to flucytosine, fluconazole, voriconazole, and am-
photericin B. After removal of the central venous catheter and initiation of fluconazole 
treatment, the patient’s condition gradually improved, and she was cleared for discharge 
from our hospital. Both clinicians and microbiologists should be aware of predisposing 
factors to C. dubliniensis candidemia in order to promote early diagnosis and appropriate 
treatment.
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INTRODUCTION
The laboratory identification of pathogenic yeasts is very impor-
tant because of the increasing incidence of opportunistic infec-
tions and the rise in resistant strains of yeasts. The widespread 
use of immunosuppressive agents or broad-spectrum antibiotics 
predisposes patients to subsequent opportunistic fungal infec-
tions. The majority of these infections are caused by Candida al-
bicans, but in recent years, close to 50% of all episodes of can-
didemia have been caused by non-albicans species [1-3]. The 
incidence of candidemia due to these uncommon Candida spp. 
appears to be increasing, and certain species, such as C. dubli-
niensis, have been reported to be less susceptible or resistant to 
antifungal agents [4].
 C. dubliniensis was first isolated in 1995 from the oral cavities 
of HIV-infected individuals and AIDS patients [5]. While the clin-
ical significance of C. dubliniensis seems to involve its associa-
tion with HIV infection, C. dubliniensis has also been increasingly 
found in individuals who are not infected with HIV [6, 7]. Identifi-
cation of C. dubliniensis can be problematic in routine clinical 
practice due to its phenotypic resemblance to C. albicans [8]. 
Because there have been no prior case reports of C. dubliniensis 
candidemia in Korea, the prevalence of this species among the 
Korean population remains unclear. In this article, we report the 
first case of C. dubliniensis candidemia in Korea, which was 
identified using both phenotypic and genotypic methods.
CASE REPORT
A 64-yr-old woman who presented with partial seizures, drowsi-
ness, and recurrent fever was transferred to our hospital with a 
central venous catheter and L-tube. She had been treated for 
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fever with ceftriaxone at another hospital, but had shown no 
clinical improvement. On admission to our hospital, the patient, 
who also had a medical history of hypertension, had a body tem-
perature higher than 39°C. Viral meningitis and bacterial pneu-
monia were immediately suspected. Laboratory investigation re-
vealed a leukocyte count of 5,920/mm3 with 87% neutrophils, 10 
g/dL of hemoglobin, and a platelet count of 136,000/mm3. The 
serum level of C-reactive protein was elevated (270.72 mg/L). 
The patient underwent cerebrospinal fluid (CSF) tap, chest X-
ray examination, and two sets of peripheral blood cultures, and 
was started on an empirical antibiotic combination of ticarcillin/
clavulanate for the bacterial pneumonia and on acyclovir for the 
suspected viral meningitis for 4 days. However, this treatment 
yielded no clinical improvement. More than 3 days after admis-
sion, the patient’s fever persisted, and her mental status change 
was exacerbated by convulsions. The patient continued to have 
fevers of >39°C and was subsequently transferred to a medical 
intensive care unit (ICU). 
 The blood cultures obtained to evaluate the fever on the first 
day of admission were negative. Three days after admission, a 
second blood culture was performed and microbial growth was 
observed after 24 hr of incubation in the BacT/Alert 3D system 
(bioMerieux, Durham, NC, USA). The same microorganisms 
were found in culture sets of central venous catheter tips, in bile 
cultures, and in a third blood culture taken 3 days after the sec-
ond blood culture. A subculture on sheep blood agar plates was 
performed for the peripheral blood and other specimens. After 
24 hr of incubation on sheep blood agar plates at 35°C in the 
presence of 5% CO2, we observed smooth and white colonies, 
suspected to be Candida spp. Isolates were subcultured on Sa-
bouraud dextrose agar (SDA) plates for further phenotype test-
ing. C. albicans ATCC 14053 and C. dubliniensis ATCC MYA-646 
were used as reference strains.
 Identification was made on the basis of a combination of vari-
ous phenotypic methods and confirmed by species-specific 
multiplex PCR. Isolates produced germ tubes in human pooled 
serum in 3 hr at 37°C (Fig. 1) and did not grow at 45°C for 96 hr 
on SDA plates. Isolates were cultured on CHROMagar Candida 
media (Becton Dickinson, Sparks, MD, USA) at 35°C for 48 hr. 
The resulting colonies were dark green in color, which differs 
from the light to medium green color of the more commonly ob-
served C. albicans (Fig. 2). These isolates were identified as C. 
dubliniensis using the Vitek 2 ID-YST System (bioMerieux Inc., 
Hazelwood, MO, USA) (probability, 91.0%) and the latex aggluti-
nation test using Bichro-Dubli Fumouze (Fumouze Diagnostics, 
France) (Fig. 3) [9]. To confirm this finding, we performed spe-
cies-specific multiplex PCR using the Seeplex Candida Detec-
Fig. 2. Candida dubliniensis on CHROMagar Candida plate incu-
bated at 35°C for 48 hr (left, C. dubliniensis; right, C. albicans).
Fig. 3. Latex agglutination test for Candida dubliniensis: left, C. dub-
liniensis; middle, C. glabrata; right, C. albicans.
Fig. 1. (A) Candida dubliniensis and (B) Candida albicans ATCC 14053 
showing germ tube formation in human pooled serum (×1,000).
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tion kit (Seegene, Seoul, Korea), which contained two sets of 
primer mixtures for the detection of 8 different Candida spp. [10]. 
The isolates were confirmed as C. dubliniensis. 
 An antifungal susceptibility test was performed using the Vi-
tek 2 system (bioMerieux Inc.), and we determined that the iso-
lates were susceptible to flucytosine, fluconazole, voriconazole, 
and amphotericin B. On the basis of the results of the suscepti-
bility tests, the patient was treated with fluconazole for 4 weeks. 
In addition, the central venous catheter that was the suspected 
cause of the candidemia was removed immediately after C. 
dubliniensis was identified from the second blood culture. After 
initiation of antifungal therapy and removal of the central venous 
catheter, the patient’s clinical symptoms, including the fever, 
were gradually improved. However, due to other medical prob-
lems including cholecystitis, gastric ulcer, and hypertension, the 
patient remained in the ICU for 93 days, after which she was 
discharged to another hospital. 
 
DISCUSSION
The incidence of candidemia in the overall population ranges 
from 1.7 to 10 episodes per 100,000 inhabitants, and Candida is 
one of the 10 leading causes of bloodstream infections in devel-
oped countries. An estimated 33-55% of all episodes of candi-
demia occur in the ICU environment and are associated with 
mortality rates ranging from 5% to 71% [3]. Candidemia may 
have an endogenous or an exogenous origin, and in recent 
years, a growing proportion of episodes of candidemia have 
been caused by Candida spp. other than C. albicans. There are 
a number of conditions predisposing ICU patients to candidemia, 
including prior abdominal surgery, intravascular catheters, acute 
renal failure, malignancy, vancomycin treatment longer than 3 
days, parenteral nutrition, broad-spectrum antibiotics, a pro-
longed ICU stay, the use of corticosteroids, and mucosal coloni-
zation with Candida spp. [3, 11, 12]. For the patient in this case, 
the predisposing factors included a central venous catheter, par-
enteral nutrition, broad-spectrum antibiotics, and a prolonged 
ICU stay. Among these, the central venous catheter was the most 
likely explanation for nosocomial candidemia, which is supported 
by the clinical improvement of the patient after removal of the 
catheter. A central venous catheter has also been cited as a risk 
factor for nosocomial candidemia in several reports, and removal 
of catheters has been recommended to reduce the rate of cathe-
ter-related bloodstream infection and to prevent nosocomial clus-
ters in the ICU [13, 14].
 C. dubliniensis has recently been described as an opportu-
nistic yeast that is primarily associated with oropharyngeal infec-
tions in HIV-infected patients. Unlike C. albicans, C. dublinien-
sis is rarely found in the oral microflora of normal healthy indi-
viduals, and it is responsible for as few as 2% of cases of candi-
demia (compared to approximately 65% for C. albicans) [15]. 
 Phenotypically, C. dubliniensis and C. albicans have many 
similarities, including their microscopic morphology and ability 
to form germ tubes in serum [8]. Therefore, the objective of 
most previous studies has been to distinguish C. dubliniensis 
from C. albicans or other germ tube-positive Candida species 
[16, 17]. Tests based on different phenotypic characteristics, 
such as the inability of C. dubliniensis to grow at 45°C [18], and/
or in Sabouraud dextrose broth containing 6.5% sodium chlo-
ride (NaCl) [19]; the production of abundant pseudohyphae and 
chlamydospores on Staib agar [20]; and the formation of dark 
green colonies on CHROMagar Candida medium [21], have 
been claimed to differentiate between the two species. However, 
these characteristics are not definitive, and identification of C. 
dubliniensis in routine laboratory testing remains a problem. Ad-
ditional tests, such as the latex agglutination test and molecular 
assays, are helpful in accurately differentiating between the two 
species. 
 The latex agglutination test used for this case is a commer-
cialized protocol for identifying C. dubliniensis isolates that uses 
particles coated with a monoclonal antibody, which allows for 
the specific detection of an antigen located on the surface of the 
C. dubliniensis blastoconidia [9]. The latex agglutination of C. 
dubliniensis is visible to the unaided eye. Molecular techniques 
employing PCR have also increased the accuracy of identifying 
uncommon Candida spp. Although 16S RNA gene sequencing 
is a useful and definitive method for most Candida spp., it re-
quires a specialized instrument to analyze the product. Multi-
plex PCR using a specific primer can serve as an alternative, 
easy to perform, and accurate diagnostic tool for the identifica-
tion of C. dubliniensis [10, 22, 23].
 Resistance to antifungal agents is rarely found in Candida 
spp. The fluconazole resistance rate was reported to be 2% in 
Korean patients with candidemia, and each of the Candida spp. 
that caused candidemia in that study showed susceptibility to 
voriconazole [24, 25]. However, uncommon Candida spp., such 
as C. guilliermondii, C. rugosa, and C. dubliniensis, had suscep-
tible-dose-dependent minimum inhibitory concentration (MIC) 
values for fluconazole [4]. Resistance to fluconazole has been 
reported to occur only rarely in C. albicans (0.6%), while occur-
ring more commonly in C. dubliniensis (3.1%) [2]. However, the 
vast majority of C. dubliniensis isolates identified to date are 
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susceptible to all of the commonly used antifungal agents [13]. 
C. dubliniensis isolates in the present case showed susceptibil-
ity to flucytosine, fluconazole, voriconazole, and amphotericin B, 
which corresponds with previous reports.
 In this report, we describe the case of C. dubliniensis candi-
demia in an ICU patient with pneumonia and meningitis. To our 
knowledge, this report is the first case of C. dubliniensis candi-
demia in Korea and the first case identified phenotypically and 
subsequently confirmed by molecular methods. During the di-
agnostic process, a C. dubliniensis infection should be distin-
guished from infection caused by other Candida spp., particu-
larly C. albicans. Confirmation through various methods, such 
as latex agglutination and multiplex PCR, is needed for the ac-
curate identification of isolates. Both clinicians and microbiolo-
gists should be aware of predisposing factors for C. dubliniensis 
candidemia to promote early diagnosis and appropriate treat-
ment.
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